Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Pathophysiology

Circulating Adiponectin Levels Are Reduced in Nonobese but Insulin-Resistant First-Degree Relatives of Type 2 Diabetic Patients

  1. F. Pellmé1,
  2. U. Smith1,
  3. T. Funahashi2,
  4. Y. Matsuzawa2,
  5. H. Brekke3,
  6. O. Wiklund4,
  7. M.-R. Taskinen5 and
  8. P.-A. Jansson1
  1. 1The Lundberg Laboratory for Diabetes Research, the Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
  2. 2Department of Internal Medicine and Molecular Science, Osaka University, Osaka, Japan
  3. 3Department of Clinical Nutrition, the Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
  4. 4Wallenberg Laboratory for Cardiovascular Research, the Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
  5. 5Department of Medicine, University of Helsinki, Helsinki, Finland
    Diabetes 2003 May; 52(5): 1182-1186. https://doi.org/10.2337/diabetes.52.5.1182
    PreviousNext
    • Article
    • Figures & Tables
    • Info & Metrics
    • PDF
    Loading

    Article Figures & Tables

    Tables

    • TABLE 1

      Basic characteristics, metabolic variables, lipoprotein concentrations, inflammatory markers, endothelial injury markers, and other markers in relatives and control subjects

      RelativesControl subjectsP
      SexMale (n = 45)Male (n = 40)
      Age (years)43.1 ± 8.645.1 ± 6.9
      BMI (kg/m2)25.8 ± 2.624.6 ± 2.6<0.05
      Waist circumference (cm)94 ± 0.990 ± 0.9<0.05
      Body fat (kg)19.5 ± 6.116.5 ± 6.6<0.03
      Blood pressure
       Systolic (mmHg)128 ± 16118 ± 9<0.01
       Diastolic (mmHg)76 ± 673 ± 7<0.05
      Oral glucose tolerance test
       Fasting plasma proinsulin (pmol/l)11 ± 79 ± 6
       Fasting plasma glucose (mmol/l)4.9 ± 0.54.4 ± 0.3<0.0001
       Fasting plasma insulin (pmol/l)54 ± 2448 ± 30
       Plasma glucose at 120 min (mmol/l)5.0 ± 1.24.0 ± 1.1<0.0001
       Plasma insulin at 120 min (pmol/l)246 ± 174168 ± 126<0.05
       Si (×10−4 × min−1 per μU/ml)3.3 ± 2.44.5 ± 2.6<0.01
      Insulin secretion rate
       First-phase insulin response (0–10 min) (μU/min)409 ± 305412 ± 300
      Lipoprotein concentration
       Fasting serum total cholesterol (mmol/l)4.9 ± 0.94.4 ± 1.2
       Fasting serum HDL cholesterol (mmol/l)1.15 ± 0.231.15 ± 0.45
       Fasting serum LDL cholesterol (mmol/l)3.2 ± 0.82.7 ± 0.9<0.01
       Fasting serum triglyceride (mmol/l)1.26 ± 0.601.37 ± 1.20
       Fasting plasma free fatty acid (mmol/l)0.48 ± 0.180.49 ± 0.23
       LDL size (nm)26.0 ± 1.2226.0 ± 1.20
      Inflammatory markers
       Serum C-reactive protein, (mg/l)1.28 ± 2.040.76 ± 0.68<0.1
       Plasma fibrinogen (g/l)2.55 ± 0.382.49 ± 0.52
      Endothelial injury markers
       Serum VCAM-1 (ng/ml)438 ± 72462 ± 76
       Serum ICAM-1 (ng/ml)249 ± 50233 ± 58
       Serum E-selectin (ng/ml)56.8 ± 19.651.2 ± 16.4
      Other markers
       Serum adiponectin (μg/ml)6.6 ± 1.88.1 ± 3.0<0.03
       Plasma PAI-1 (IU/ml)19.4 ± 15.413.0 ± 14.7<0.01
      • Data are mean ± SD. ICAM, intercellular adhesion molecule; VCAM, vascular cell adhesion molecule.

    • TABLE 2

      Partial correlation coefficients (r) between adiponectin and selected variables in the relatives (n = 45)

      ParameterModel 1Model 2Model 3
      Fasting plasma insulin−0.55*−0.52*−0.43†
      Fasting plasma proinsulin−0.64*−0.61*−0.56*
      Si0.41†0.34‡—
      Acute insulin response−0.40‡−0.34†−0.26
      HDL cholesterol0.48†0.43‡0.39‡
      PAI-1 activity−0.56*−0.54*−0.53*
      • Data are r. Model 1 is adjusted for age; model 2 is adjusted for age and waist; model 3 is adjusted for age, waist, and Si

      • *

        * P < 0.001;

      • †

        † P < 0.01;

      • ‡

        ‡ P < 0.05.

    PreviousNext
    Back to top

    In this Issue

    May 2003, 52(5)
    • Table of Contents
    • Index by Author
    Sign up to receive current issue alerts
    View Selected Citations (0)
    Print
    Download PDF
    Article Alerts
    Sign In to Email Alerts with your Email Address
    Email Article

    Thank you for your interest in spreading the word about Diabetes.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Circulating Adiponectin Levels Are Reduced in Nonobese but Insulin-Resistant First-Degree Relatives of Type 2 Diabetic Patients
    (Your Name) has forwarded a page to you from Diabetes
    (Your Name) thought you would like to see this page from the Diabetes web site.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Citation Tools
    Circulating Adiponectin Levels Are Reduced in Nonobese but Insulin-Resistant First-Degree Relatives of Type 2 Diabetic Patients
    F. Pellmé, U. Smith, T. Funahashi, Y. Matsuzawa, H. Brekke, O. Wiklund, M.-R. Taskinen, P.-A. Jansson
    Diabetes May 2003, 52 (5) 1182-1186; DOI: 10.2337/diabetes.52.5.1182

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    Add to Selected Citations
    Share

    Circulating Adiponectin Levels Are Reduced in Nonobese but Insulin-Resistant First-Degree Relatives of Type 2 Diabetic Patients
    F. Pellmé, U. Smith, T. Funahashi, Y. Matsuzawa, H. Brekke, O. Wiklund, M.-R. Taskinen, P.-A. Jansson
    Diabetes May 2003, 52 (5) 1182-1186; DOI: 10.2337/diabetes.52.5.1182
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Jump to section

    • Article
      • Abstract
      • RESEARCH DESIGN AND METHODS
      • RESULTS
      • DISCUSSION
      • Acknowledgments
      • Footnotes
      • REFERENCES
    • Figures & Tables
    • Info & Metrics
    • PDF

    Related Articles

    Cited By...

    More in this TOC Section

    • Podocyte EGFR Inhibits Autophagy Through Upregulation of Rubicon in Type 2 Diabetic Nephropathy
    • A High-Fat Diet Attenuates AMPK α1 in Adipocytes to Induce Exosome Shedding and Nonalcoholic Fatty Liver Development In Vivo
    • Multinucleated Giant Cells in Adipose Tissue Are Specialized in Adipocyte Degradation
    Show more Pathophysiology

    Similar Articles

    Navigate

    • Current Issue
    • Online Ahead of Print
    • Scientific Sessions Abstracts
    • Collections
    • Archives
    • Submit
    • Subscribe
    • Email Alerts
    • RSS Feeds

    More Information

    • About the Journal
    • Instructions for Authors
    • Journal Policies
    • Reprints and Permissions
    • Advertising
    • Privacy Policy: ADA Journals
    • Copyright Notice/Public Access Policy
    • Contact Us

    Other ADA Resources

    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • Scientific Sessions Abstracts
    • Standards of Medical Care in Diabetes
    • BMJ Open - Diabetes Research & Care
    • Professional Books
    • Diabetes Forecast

     

    • DiabetesJournals.org
    • Diabetes Core Update
    • ADA's DiabetesPro
    • ADA Member Directory
    • Diabetes.org

    © 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.